Adverse Effects of Low‐Dose Methotrexate in a Randomized Double‐Blind Placebo‐Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial

OBJECTIVE: Low‐dose methotrexate (LD‐MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia, leukopenia, and skin cancers, but the risks of myelosuppression and malignancy during LD‐MTX use remain incompletely described. We examined the...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanni, Kathleen M.M., Berliner, Nancy, Paynter, Nina P., Glynn, Robert J., MacFadyen, Jean, Colls, Joshua, Lu, Fengxin, Xu, Chang, Ridker, Paul M., Solomon, Daniel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738806/
https://www.ncbi.nlm.nih.gov/pubmed/33201596
http://dx.doi.org/10.1002/acr2.11187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738806/
https://www.ncbi.nlm.nih.gov/pubmed/33201596
http://dx.doi.org/10.1002/acr2.11187

Ejemplares similares